Aldeyra Therapeutics (ALDX)CFO bought ~$13K

~$13K

Approx. value · 2,500 sh @ $5.30

2,500

Holds after · shares reported

Traded

Aug 13, 2025

Filed

Aug 15, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Aug 11, 2025InsiderOfficer sold ~$114K of ALDX shares in the open market
2. Aug 13, 2025 · this disclosureInsiderCFO purchased ~$13K of ALDX shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Aldeyra Therapeutics

OQRO holds no insider, Congress, fund or contract record for Aldeyra Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ALDX page.

Other recent filings by Michael Alfieri, Principal Financial Officer

• SEC Form 4 at Aldeyra Therapeutics (ALDX)Mar 19, 2026

The full history of Michael Alfieri, Principal Financial Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Aldeyra Therapeutics

• SEC Form 4Jun 5, 2026
• SEC Form 13F-HRMay 29, 2026
• SEC Form 4Mar 20, 2026
• SEC Form 4Mar 19, 2026
• SEC Form 13F-HRFeb 17, 2026
• SEC Form 13F-HRNov 14, 2025

Everything OQRO holds on this company is on its ALDX page.